Desiree H.

Attention Life Science Professionals! 🔥 ANOTHER HOT TOPIC ALERT! 🧪🔬 Some More Good News in the Life Sciences! Check out the summary below regarding the 3,000 jobs created in Boston area in 2024. Share your thoughts in the comments! And if you are looking for folks, please let us know! hashtag #lifesciences #biotech #pharma #medicaldevice #diagnostics #hiring2024 #boston The Richmond Group USA

6

📣 For those going to the ASA Biopharmaceutical Section Statistics Workshop this week, Stop by Booth #18 to meet my teammates: Lei Wang, Helena Fan, & Bill Emker. American Statistical Association - ASA #pharma #fda #statistics #statisticians #biostatisticians #biostatistics #datascience

1

The fourth quarter of 2024 is critical for the biotech industry, with 5 major FDA approval decisions on the horizon. These upcoming verdicts could impact everything from treatments for #cancer to #rarediseases 🧬 Stay ahead of the latest in #biotech and learn how these #FDA decisions could shape the future of healthcare.

12

Will we see more opportunity for Validation Professionals in 2025? The validation market is heating up as big players and industry shifts create new opportunities for CQV and Validation professionals. Here’s what’s driving the change: 📈 Biotech Expansion — With huge investments from Amgen ($1.5B), J&J ($2B), and Fujifilm Diosynth ($1.2B), demand for CQV engineers is set to rise. With many opportunities across Aseptic Processing, Equipment Validation and Automation. ⚙️ Tech-Enabled Validation — The shift to digital validation systems and paperless CQV is here. Companies are turning to cloud-based tools to streamline data capture and boost audit-readiness. 🌿 Sustainable Validation — As biopharma adopts green manufacturing, validation engineers must ensure compliance for eco-friendly production and energy-efficient systems. 💥 What’s Next? With 2025 a few weeks away I am looking to connect with CQV and Validation Consultants to discuss projects upcoming in Q1 next year. 👉 Do you think 2025 will have more opportunity that 2024? Let me know! #Validation #CQV #PharmaTrends #Biopharma #Innovation #AsepticProcessing #CellAndGeneTherapy #Sustainability

15

1 Comment

🎉 BioSpace’s 2025 Best Places to Work in Biopharma Are Here! 🏆 BioSpace has revealed its 50 top biopharma companies to work for in 2025, chosen from over 3,600 life sciences professionals. This year’s list features Moderna (top large employer) and Sutro Biopharma, Inc. Biopharma (top small employer) for their exceptional commitment to employee well-being, innovation, and career growth. Companies were rated on 8 critical factors, including diversity, flexibility, and culture. Leaders like Eli Lilly and Company, Regeneron, and Apogee Therapeutics round out the top picks, showcasing excellence in the industry! 🌍💼 Key Highlights: - Moderna champions learning with Moderna University and inclusive spaces through nine employee resource groups. - Sutro Biopharma emphasizes mission-driven collaboration, offering career development options like job rotation and mental health support. Congratulations to all the winners making strides in transforming life sciences workplaces! 🌟 #BiotechExcellence #BestPlacestoWork #EmployeeExperience #LifeSciences

2

1 Comment

Enjoying the COG New England conference - meeting great people. #COG #COGNewEngland #ClinicalTrials #ClinicalResearch #ClinicalOutsourcing Most interesting Panel yesterday with biotech CEOs from Massachusetts who were cautiously optimistic about the life science investment environment. Some themes: ·       The power of big pharma money currently. ·      The inflection point for further investment has shifted further along the “get great data” timeline so you have to do more with your money. ·      A natural reset has occurred – cheap money from years gone by in a low interest rate environment is no longer around and investors are looking for value now. ·      Newer technologies including gene therapy may struggle as investors seek quicker value. ·      The need for cashing out and re-cycling. We need a wave of IPOs and exits to recycle investment cash. ·      A hope for a more positive investment environment as interest rates fall but caution given no-one knows what election season will bring! ·      Hot areas include: Obesity/Cardiobetes/ADCs/Radiotherapies/Neuro/Autoimmune   In all a very impressive bunch of CEOs and some cause for hope and a rising tide this year.

26

🚨 Pfizer & Flagship Pioneering Expand Their Billion-Dollar Collaboration! 🚨 Pfizer and Flagship are doubling down on obesity and lung cancer with innovative partnerships: 💡 Ampersand Biomedicines: Leveraging their AND platform to target metabolic pathways for obesity treatment. 💡 Montai Therapeutics: Using computational tools to decode biological pathways and develop precision small molecules for lung cancer. This marks the 3rd & 4th partnerships under their 10-program pact, showcasing a new Innovation Supply Chain in biopharma. #Biotech #Collaboration #Innovation #Pfizer #FlagshipPioneering #Healthcare

3

1 Comment

At BlueGene Search, we don’t just recruit talent—we build the teams that bring #biotech innovations to life. Whether you're launching a new therapy, scaling operations, or filling key gaps in your organization, our specialized expertise delivers solutions tailored to the unique challenges of life sciences. Here’s how we make an impact: ✅ Launch Team Builds: We craft launch-ready teams, sourcing the best talent to hit the ground running in fast-paced biotech environments. Your innovation deserves a flawless rollout, and we’re here to assemble the team that makes it happen. ✅ Fractional Talent Acquisition: Need expert support without the full-time commitment? Our fractional talent acquisition services provide you with on-demand recruitment expertise, scaling your team at the right pace for your growth. ✅ Life Science Recruiting: We live and breathe biotech and pharma. With years of experience and deep networks, we connect you to candidates who have the skills and passion to drive your mission forward. ✅ Full-Service Agency: From sourcing to onboarding, we’re your end-to-end talent solution. BlueGene Search takes the guesswork out of hiring, allowing you to focus on what matters most—transforming lives through science. The right team isn’t a luxury—it’s a necessity. Let us help you find yours. 👉 Interested in learning more? Let’s connect to discuss how BlueGene Search can support your talent needs. #Biotech #LifeSciences #Recruiting #TalentAcquisition #FractionalRecruiting #LaunchTeam #BlueGeneSearch

17

🌟 Driving Innovation in Rare Disease R&D! 🌟 Despite affecting 30M people in the U.S., rare diseases still face significant underfunding for drug development. Big Pharma investments remain limited due to small patient populations and traditional ROI models. 💊 However, creative strategies are reshaping this landscape: 🔹 Zevra Therapeutics uses royalty financing, M&A, and shared infrastructure. 🔹 Ultragenyx reinvests revenue from existing therapies and leverages Priority Review Vouchers. 🔹 Deerfield Management explores philanthropic and non-profit development models. Collaboration and supportive policies like the Orphan Drug Act and FDA’s Rare Disease Innovation Hub are essential for progress. #RareDiseases #Innovation #Biopharma #HealthcareSolutions #OrphanDrugs

3

1 Comment

Random Testing—Have You Considered Oral Fluid? Random testing is essential for maintaining a drug-free workplace. Oral fluid testing offers flexibility and faster collection times. Have you considered it for your random drug testing program? 👉 What Challenges Are You Facing With Random Drug Testing? Call Us at (800) 269-0502 or [email protected]. Let Us Review Your Policy for FREE! #RandomDrugTesting #OralFluidTesting #DrugTesting #SafetyCulture #WorkplaceSafety #HRBestPractices #DrugFreeWorkplace

1

🎉 Big News from NeoGenomics Laboratories! 🧬💡 NeoGenomics just secured New York State Department of Health approval for its Neo Comprehensive and NeoType DNA & RNA Lung NGS tests! 🎯 These advanced tests are now available to oncologists in New York, aiming to enhance diagnostic precision and cost-effectiveness for cancer treatment. The Neo Comprehensive panel covers 517 genes across multiple tumors, while NeoType focuses on actionable mutations in lung cancer. #CancerResearch #NGSTesting #LungCancer #PrecisionOncology #NeoGenomics #InnovationInHealthcare #Genomics #PersonalizedMedicine

5

1 Comment

The Biopharma Job Market in 2024: A Reality Check I feel compelled to address some misconceptions about the current job market. While some recruiters may be expressing optimism about hiring picking up or the market turning around, the data tells a different story. Let's look at the facts: Layoff Trends: Q2 2024 saw a significant increase in biopharma layoffs, with at least 7,616 workers impacted. This is more than triple the 2,398 layoffs reported in Q1 2024. Major Players Affected: Industry giants like Novartis, Indivior, CureVac, and Takeda have all announced substantial job cuts in recent months. Ongoing Restructuring: Many companies are still in the midst of restructuring efforts, with some planning layoffs that will continue into late 2024 and beyond. Biotech Volatility: While there are pockets of growth, particularly in well-funded startups, the overall biotech sector remains volatile. What This Means for Job Seekers: Be Cautious: Exercise caution when hearing overly optimistic projections from recruiters. Always verify claims with industry data. Stay Informed: Keep abreast of industry trends, company financials, and pipeline news to make informed decisions. Diversify Your Search: Consider roles in emerging biotech startups or adjacent industries that value pharma experience. Enhance Your Skills: Focus on developing skills that are in high demand, such as data analytics, digital health, or regulatory affairs. Network Strategically: Build relationships within the industry, not just for immediate opportunities but for long-term career growth. As recruiters, our role is to provide accurate, data-driven insights to both clients and candidates. While we all hope for market improvement, it's crucial to approach the current landscape with realism and strategic thinking. What strategies are you employing in this challenging market? Let's discuss in the comments. #PharmaceuticalIndustry #BiotechJobs #CareerAdvice #RecruitmentTrends

57

10 Comments

The Q3 Job Market Report from BioSpace just dropped, and you definitely want to check it out! The life sciences job market is going through some big changes, and keeping up with the latest info is super important for navigating it all. According to the new BioSpace data, there are some challenges but also plenty of opportunities coming up! 🔍 Key Insights from BioSpace's Q3 2024 Report: 1. Decrease in Job Postings:   - There were 21,548 jobs live on BioSpace in Q3 2024.   - This is a 12% decrease from 24,503 jobs in Q3 2023. 2. Increase in Job Competition:   - The job response rate (percentage of people applying after viewing) jumped from 9.8% to 14.8%, a 51% increase year-over-year.   - Notably, from July to September 2024, the response rate surged from 14.5% to 18.4%, a 26.9% increase. 3. Top States for Job Openings:   - California: 3,769 jobs   - Massachusetts: 3,110 jobs   - New Jersey: 2,513 jobs   - Illinois: 2,452 jobs   - New York: 1,717 jobs 4. Impact of Layoffs:   - In Q3 2024, there were 54 rounds of layoffs in biotech and pharma, affecting at least 3,700 employees.   Significant layoffs included:    - FibroGen, Inc.: Let go of 75% of its U.S.-based workforce (~356 people).    - GRAIL: Laid off about 350 employees.    - BioMarin Pharmaceutical Inc.: Cut 225 positions globally.    - Johnson & Johnson & Bayer: Combined layoffs of 288 employees in New Jersey. 💡 What This Means for You: - Increased Competition: With fewer job postings and more professionals in the market, it's crucial to differentiate yourself. - Strategic Job Hunting: According to Carina Clingman, PhD, CEO of Recruitomics Consulting, fall is prime time for job hunting in biotech. Companies aim to fill positions before the budget cycle ends around Thanksgiving. 📈 Emerging Opportunities:  - Johnson & Johnson is investing $2 billion in a new biologics manufacturing plant in Wilson, North Carolina, expected to create 420 new full-time, highly skilled jobs. Construction begins in the first half of 2024.  - Eli Lilly and Company is committing $4.5 billion to build a facility in Lebanon, Indiana, housing research and manufacturing. Set to open in late 2027, it will employ about 400 new engineers, scientists, lab technicians, and operations personnel.  - MassBio's 5-Year Plan: Aiming to create hundreds of new biopharma and life sciences positions in Massachusetts by 2030, focusing on supporting early-stage biotech growth. 🚀 Tips to Stay Ahead: - Update Your Skills: Leverage this time to enhance your expertise and stay competitive. - Network: Engage with industry peers and attend virtual or in-person events. - Stay Informed: Keep an eye on emerging biotech hubs and companies expanding their workforce. - Be Proactive: Tailor your applications and highlight how you can add value in this dynamic environment. Share your experiences or tips below. #Biotech #Pharma #JobMarket #CareerGrowth #LifeSciences

4

🗞 Breaking news 🤩 Genezen acquire uniQure's commercial GT manufacturing ops in Lexington!! This strategic acquisition will enable Genezen to deliver late-phase and commercial gene therapy development and manufacturing services to customers around the world. Check out full article below👇 #CDMO #Genezen #GeneTherapy

18

Mark your calendars for the 29th Annual Executive War College, where Labcorp thought leaders will join panels to discuss adding value to payers and health plans. We’ll discuss the latest trends in laboratory and pathology mergers and acquisitions as well. Our friends from Visiun will also be there. Check out the agenda. #EWC2024 #Pathology #Strategy

1

🚀 GSK Acquires Chimagen Biosciences CD19/CD20 Trispecific T Cell Engager: Advancing B-Cell Autoimmune Therapy! In a strategic $300M acquisition, GSK recently secured Chimagen's CMG1A46, a trispecific T cell engager targeting CD19 and CD20 on B cells to treat autoimmune diseases like lupus. This cutting-edge TCE is designed to precisely deplete harmful B cells in the blood and tissue while avoiding typical toxicities. Biocytogen supports this breakthrough with humanized mouse models, empowering researchers to refine these therapies further! 🧬 #AutoimmuneResearch #Immunotherapy #Biotech #Innovation #BCellTherapies #DrugDiscovery #LifeSciences

3

1 Comment

🚨 Breaking News in Multiomic Innovation! 🌍 Tagomics and Agilent Technologies have teamed up to revolutionise genomic and epigenetic profiling! 🎉 This strategic comarketing agreement integrates Tagomics' Interlace platform with Agilent's SureSelect library prep and cancer panels. The unified workflow offers select customers unprecedented insights into epigenetic, genetic, and fragmentomic features, unlocking deeper biological understanding. 🧬 Together, these platforms aim to accelerate the development of cutting-edge diagnostics and therapeutic solutions. 💡 #Genomics #Epigenetics #Multiomics #Innovation #HealthcareTech

2

1 Comment

💊 Amgen's Monthly Obesity Drug, MariTide: Phase 2 Results Are In! 🌟 Amgen has unveiled phase 2 data for MariTide, its innovative monthly obesity treatment. While the results show promising weight loss efficacy, investors remain cautious. Here's a snapshot: ✅ Efficacy Highlights: 20% average weight loss over 52 weeks at the 280-mg dose for individuals without type 2 diabetes. 17% weight loss in participants with type 2 diabetes. No weight loss plateau observed, suggesting potential for continued reductions beyond a year. ✅ Why It Stands Out: Monthly or less frequent dosing vs. weekly options like Eli Lilly’s Zepbound or Novo Nordisk’s Wegovy. Clinically meaningful cardiometabolic improvements (e.g., blood pressure, triglycerides, C-reactive protein). Minimal side effects, with nausea/vomiting being transient and mild, and no changes in bone mineral density reported. 🤔 The Investor Perspective: Analysts see results as “on par” with Zepbound, but differentiation is limited to dosing frequency. Shares fell 10% after the announcement, reflecting the need for stronger competitive advantages. 🚀 What’s Next: Amgen is advancing to phase 3 trials under the MARITIME program, aiming to explore obesity and related conditions further. With progressive weight loss, improved HbA1C, and patient-friendly dosing, MariTide could still emerge as a compelling option in the growing obesity treatment market. 💬 What do you think about the potential of monthly dosing as a game-changer in obesity treatment? #PharmaInnovation #ObesityTreatment #Amgen #ClinicalTrials #WeightLoss #GLP1 #HealthcareTransformation

1

1 Comment